AUTHOR=Strazhesko Irina D. , Tkacheva Olga N. , Akasheva Dariga U. , Dudinskaya Ekaterina N. , Plokhova Ekaterina V. , Pykhtina Valentina S. , Kruglikova Anna S. , Kokshagina Natalia V. , Sharashkina Natalia V. , Agaltsov Mikhail V. , Kashtanova Daria A. , Vygodin Vladimir A. , Ozerova Irina N. , Skvortsov Dmitry A. , Vasilkova Daria , Boytsov Sergey A. 

TITLE=Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases

JOURNAL=Frontiers in Pharmacology

VOLUME=7

YEAR=2016

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00347

DOI=10.3389/fphar.2016.00347

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Telomerase activity (TA) is considered as the biomarker for cardiovascular aging and cardiovascular diseases (CVDs). Recent studies suggest a link between statins and telomere biology that may be explained by anti-inflammatory actions of statins and their positive effect on TA. Until now, this effect has not been investigated in prospective randomized studies. We hypothesized that 12 months of atorvastatin therapy increased TA in peripheral blood mononuclear cells.</p><p><bold>Methods:</bold> In a randomized, placebo-controlled study 100 hypercholesterolemic patients, aged 35–75 years, free of known CVDs and diabetes mellitus type 2 received 20 mg of atorvastatin daily or placebo for 12 months. TA was measured by quantitative polymerase chain reaction.</p><p><bold>Results:</bold> At study end, 82 patients had sufficient peripheral blood mononuclear cells needed for longitudinal analysis. TA expressed as natural logarithms changed from 0.46 ± 0.05 to 0.68 ± 0.06 (<italic>p</italic> = 0.004) in the atorvastatin group and from 0.67 ± 0.06 to 0.60 ± 0.07 (<italic>p</italic> = 0.477) in the control group. In multiple regression analysis, atorvastatin therapy was the only independent predictor (<italic>p</italic> = 0.05) of the changes in TA independently of markers of chronic inflammation and oxidative stress. Atorvastatin therapy was associated with increases in interleukin-6 within the normal range and a tendency toward reduction in blood urea.</p><p><bold>Conclusion:</bold> These initial observations suggest atorvastatin can act as telomerase activator and potentially as effective geroprotector.</p><p><bold>Trial registration:</bold> The trial was registered in ISRCTN registry ISRCTN55050065.</p>